In today’s briefing:
- Young Poong Precision (036560 KS) Also Now Trading Through Terms
- Details of MBK’s Four Major Concerns on Management of Korea Zinc
- Will New KOSDAQ 150 Member HLB Therapeutics Show Webzen-Like Price Moves?
Young Poong Precision (036560 KS) Also Now Trading Through Terms
- On the 13th September, MBK joined Young Poong (000670 KS) in seeking control of Korea Zinc (010130 KS) via Partial Tender Offers for KZ and Young Poong Precision (036560 KS).
- This situation has been canvassed by analysts here at Smartkarma; with increasing expectation the Choi family makes a counterbid.
- This insight analyses the fair value of YPP. No matter how you slice it, the Offer Price is punchy. Perhaps not punchier enough.
Details of MBK’s Four Major Concerns on Management of Korea Zinc
- In this insight, we discuss in detail MBK’s four major concerns on the management of Korea Zinc.
- We believe that MBK has legitimate concerns on especially the three factors including poor investments, deteriorating profitability, and increase in equity capital/disposal of treasury shares.
- If and when the 2 trillion won+ is raised, then it could lead to another tender offer and the four concerns highlighted in this insight become much more important.
Will New KOSDAQ 150 Member HLB Therapeutics Show Webzen-Like Price Moves?
- Jeisys Medical’s getting booted from the KOSDAQ 150, and HLB Therapeutics is stepping in as the new addition. This change will officially hit the book on Wednesday, September 25.
- HLB Therapeutics, with a ₩0.70T market cap and 87% float, is set for a 0.51% weight in KOSDAQ 150, triggering over 2 million shares in passive buying: 3.26x 30-day ADTV.
- With today’s after-hours volume spike in HLB Therapeutics, we’re likely to see some price action from early movers spilling into Monday’s open, similar to what we saw with Webzen.